Gene therapy, including gene addition, inactivation, and editing, offers a promising alternative to address familial hypercholesterolemia more effectively.
Gene therapy, including gene addition, inactivation, and editing, represents a promising and evolving therapeutic landscape for the management of familial hypercholesterolemia.
Familial hypercholesterolemia (FH) is a genetic disorder that affects 1 in 300 people, leading to high cholesterol levels and significantly increased cardiovascular risk. The limitations of existing FH treatments underscore the need for innovative therapeutics, and gene therapy offers a promising alternative to address FH more effectively. In this review, we survey approved gene therapy drugs first and then delve into the landscape of gene addition, gene inactivation, and gene editing therapies for hypercholesterolemia, highlighting both approved interventions and those in various stages of development. We also discussed recent advancements in gene editing tools that are essential for their application in gene therapy. Safety considerations inherent to gene therapy are also discussed, emphasizing the importance of mitigating potential risks associated with such treatments. Overall, this review highlights the progress and prospects of gene therapies for FH treatments, underscoring their potential to revolutionize the management of this prevalent and challenging condition.
Luo et al. (Fri,) conducted a review in Familial hypercholesterolemia. Gene therapy was evaluated. Gene therapy, including gene addition, inactivation, and editing, offers a promising alternative to address familial hypercholesterolemia more effectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: